Keyphrases
Solid Organ Transplant Recipients
69%
Diarrhea
51%
COVID-19
43%
Infectious Diseases
33%
Transplantation
32%
Epidemiology
31%
Cytomegalovirus
26%
Norovirus
25%
Patients with COVID-19
23%
Cytomegalovirus Infection
21%
Fungal Infection
21%
Retrospective Cohort Study
21%
Cancer Treatment
19%
Single-center Experience
18%
Heart Transplantation
18%
Virus-associated Cancer
18%
Pneumocystis Jirovecii
18%
Cancer Prevention
18%
Sexually Transmitted Infections
18%
Kidney Transplant Recipients
18%
Solid Organ Transplantation
16%
Stem Cell Transplantation
15%
Risk Factors
14%
Invasive Fungal Infection
13%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
13%
Community-onset
13%
Diagnostic Performance
13%
Viral Infection
13%
Single Center
11%
Gastroenteritis
11%
Lymphopenia
11%
Genome Analysis
11%
Retrospective Analysis
11%
Alemtuzumab
11%
Early Treatment
11%
Patients with Cancer
10%
Vancomycin
10%
Opportunistic Infections
10%
Hospitalized Patients
10%
Late-onset
10%
Optimal Strategy
10%
Solid Organ Transplant
10%
Polymerase Chain Reaction
10%
P. Lilacinum
9%
Purpureocillium Lilacinum
9%
Diagnosis Treatment
9%
Fluorescence Endoscopy
9%
Cathepsin Activity
9%
Mycobacterium Xenopi
9%
Invasive Pulmonary Aspergillosis
9%
Medicine and Dentistry
Infection
100%
Transplantation
57%
Pathogen
45%
Diarrhea
39%
COVID-19
37%
Virus Infection
31%
Cohort Effect
31%
Diagnosis
29%
Malignant Neoplasm
22%
Cancer Treatment
19%
Heart Transplantation
18%
Pneumocystis Jirovecii
18%
Kidney Graft
18%
Solid Organ Transplantation
17%
Cytomegalovirus
16%
Mycosis
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Cytomegalovirus Infection
14%
Norovirus
14%
Systemic Mycosis
13%
Antivirus Agent
12%
Immunocompromised Patient
12%
Lymphocytopenia
12%
Antifungal Agent
12%
Case-Control Study
11%
Enterocolitis
11%
Endoscopy
10%
Monoclonal Antibody
10%
Polymerase Chain Reaction
10%
Human Immunodeficiency Virus
10%
Colitis
10%
Cancer
10%
Outpatient
10%
Drug Therapy
10%
Whole Genome Sequencing
10%
Retrospective Cohort Study
9%
Skin Infection
9%
Primary Prevention
9%
Gonorrhea
9%
Chlamydiae
9%
Dysplasia
9%
Surgery
9%
Osteomyelitis
9%
Cross Sectional Study
9%
Allogeneic Stem Cell Transplantation
9%
Liver Cirrhosis
9%
Antibiotic-Associated Diarrhea
9%
Early Diagnosis
9%
Trichomoniasis
9%
Artificial Respiration
9%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
40%
Diarrhea
39%
Virus Infection
33%
Infectious Agent
30%
Cohort Study
20%
Cytomegalovirus
20%
Norovirus
16%
Disease
15%
Cytomegalovirus Infection
12%
Vancomycin
12%
Monoclonal Antibody
12%
Alemtuzumab
11%
Case-Control Study
10%
Malignant Neoplasm
10%
Antivirus Agent
10%
Neurotoxicity
9%
Nephrotoxicity
9%
Aciclovir
9%
BK Virus
9%
Kidney Disease
9%
Coronavirinae
9%
Leukemia
9%
Systemic Mycosis
9%
Bacterial Peritonitis
9%
Liver Cirrhosis
9%
Norovirus Infection
9%
Critical Illness
9%
Immunocompromised Patient
9%
Hematologic Malignancy
9%
Anticoagulant Agent
9%
Osteomyelitis
9%
Trichomoniasis
9%
Secondary Syphilis
9%
Ganciclovir
9%
Gonorrhea
9%
Chlamydiae
9%
Human Papillomavirus
9%
Dimorphic Fungal Infection
9%
Pyrrole
9%
Acute Kidney Failure
7%
Varicella Zoster Virus
7%
Hepatitis B Virus
6%
Virus Hepatitis
6%
HIV
5%